Cases 1 - 10 of 13
In Re: Ozempic (Semaglutide) Patent Litigation
as 1:2022md03038
Not Classified By Court:
Zydus Lifesciences Limited, Ozempic (Semaglutide) Patent Litigation, Novo Nordisk Inc. and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
In Re: Xarelto (Rivaroxaban) ('310) Patent Litigation
as 1:2021md03017
In Re:
Xarelto (Rivaroxaban) ('310) Patent Litigation
Not Classified By Court:
Clerk of MDL Panel, Lupin Limited, Lupin Pharmaceuticals, Inc. and others
Counter Defendant:
Bayer Pharma AG, Bayer AG and Janssen Pharmaceuticals, Inc.
Defendant:
ScieGen Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
In re: Entresto (Sacubitril/Valsartan) Patent Litigation
as 1:2020md02930
Counter Claimant:
Biocon Pharma Limited, Teva Pharmaceuticals USA, Inc., Alkem Laboratories Ltd. and others
Not Classified By Court:
Hetero USA Inc.,, Torrent Pharma Inc., Zydus Pharmaceuticals (USA) Inc. and others
In Re:
Entresto (Sacubitril/Valsartan) Patent Litigation
Counter Defendant:
Novartis Pharmaceuticals Corporation
Defendant:
Noratech Labs, Inc.
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
In re: Palbociclib Patent Litigation
as 1:2019md02912
Not Classified By Court:
Aizant Drug Research Solutions Pvt. Ltd., Hetero USA Inc., Teva Pharmaceuticals USA, Inc. and others
In Re:
In re: Palbociclib Patent Litigation
Cause Of Action: 35 U.S.C. § 271
In re: Sitagliptin Phosphate ('708 & '921) Patent Litigation
as 1:2019md02902
Counter Defendant:
Merck Sharp & Dohme Corp.
Not Classified By Court:
Teva Pharmaceuticals USA, Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Limited and others
Counter Claimant:
Macleods Pharmaceuticals Limited
In Re:
In re: Sitagliptin Phosphate ('708 & '921) Patent Litigation
Defendant:
Accord Healthcare, Inc., Teva Pharmaceutical Industries Ltd., Inventia Healthcare Ltd. and others
Cause Of Action: 35 U.S.C. § 271 Patent Infringement
In re: Auryxia (Ferric Citrate) Patent Litigation
as 1:2019md02896
Not Classified By Court:
Chemo Research S.L., Insud Pharma S.L., Teva Pharmaceuticals USA, Inc. and others
Counter Defendant:
Keryx Biopharmaceuticals, Inc., Panion & BF Biotech, Inc. and Chen Hsing Hsu
Counter Claimant:
Lupin Atlantis Holdings SA and Lupin Ltd.
In Re:
In re: Auryxia (Ferric Citrate) Patent Litigation
Cause Of Action: 35 U.S.C. § 271
In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation
as 1:2019md02895
Not Classified By Court:
UFCW Local 1500 Welfare Fund, Actavis Pharma Inc., Cipla Ltd. and others
Plaintiff:
Cesar Castillo, Inc. and KPH HEALTHCARE SERVICES, INC.
In Re:
In re: Sensipar (Cinacalcet Hydrochloride Tablets) Antitrust Litigation
Cause Of Action: 15 U.S.C. § 1
In re: Kerydin (Tavaborole) Topical Solution 5% Patent Litigation
as 1:2019md02884
Counter Claimant:
Glasshouse Pharmaceuticals Limited Canada
Not Classified By Court:
Taro Pharmaceuticals U.S.A., Inc., Aurobindo Pharma Limited, Zydus Pharmaceuticals (USA) Inc. and others
In Re:
Kerydin (Tavaborole) Topical Solution 5% Patent Litigation
Counter Defendant:
Anacor Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271
In Re: BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litigation
as 2:2014md02510
Counter Defendant:
Invitae Corporation, Myriad Genetics, Quest Diagnostics and others
Counter Claimant:
Pathway Genomics and Ambry Genetics
Undetermined:
Labroratory Corporation of America Holdings, AARP, GeneDX and others
In Re:
BRCA1- and BRCA2- Based Hereditary Cancer Test Patent Litigation
Cause Of Action: 35 U.S.C. § 0271
In Re: Bear Creek Technologies Inc. ('722) Patent Litigation
as 1:2012md02344
Counter Claimant:
Qwest Communications International Inc., Mediacom Broadband LLC, 8x8, Inc. and others
Not Classified By Court:
Charter Communications Inc., Media Broadcom, LLC, Cox Communications Inc. and others
Counter Defendant:
Bear Creek Technologies Inc. ('722) Patent Litigation
Cause Of Action: 35 U.S.C. § 271
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
